Photo by nampoh from unsplash
The phase III REFLECT study utilized bodyweight‐based lenvatinib dosing in patients with unresectable hepatocellular carcinoma, based on results of the phase II Study 202. This post hoc analysis compared efficacy… Click to show full abstract
The phase III REFLECT study utilized bodyweight‐based lenvatinib dosing in patients with unresectable hepatocellular carcinoma, based on results of the phase II Study 202. This post hoc analysis compared efficacy and safety in patients with lower and higher bodyweights.
Keywords:
bodyweight based;
hepatocellular carcinoma;
safety;
efficacy;
impact bodyweight;
based starting
Journal Title: Hepatology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Hepatology Research
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!